☆ 4.3 Article

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

JOURNAL OF DIABETES INVESTIGATION (2011)

Get Full Text
Add to Collection

Journal

JOURNAL OF DIABETES INVESTIGATION
Volume 2, Issue 6, Pages 441-447

Publisher

WILEY
DOI: 10.1111/j.2040-1124.2011.00128.x

Keywords

GLP-1 receptor agonist; Liraglutide; Type 2 diabetes mellitus

Categories

Endocrinology & Metabolism

Funding

  1. Novo Nordisk Pharma Ltd.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Aims/Introduction: We compared the safety and efficacy of liraglutide vs glibenclamide in patients with poorly controlled (HbA1c, 7.410.4%) type 2 diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.